Daxor Corporation announced new pilot randomized control trial (RCT) data from Duke Heart validating the greater accuracy of the Company's BVA-100 diagnostic in optimizing decongestion therapy for heart failure patients and pointed to a strong signal toward reducing hospital length of stay in a pilot cohort of 31 patients. Data were presented as a moderated featured abstract at the Technology Heart Failure Therapeutics Conference, which focuses on device and technology-based treatments in heart failure, held March 20-22, 2023 in Boston, Mass. Blood volume analysis (BVA) was used in hospitalized heart failure patients to study the effects of BVA-guided care on decongestion therapy and outcomes versus standard of care.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.59 USD | +2.46% | +2.46% | -0.10% |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-0.10% | 45.08M | |
+13.79% | 9.73B | |
-0.70% | 5.53B | |
+5.79% | 5.15B | |
+24.26% | 4.87B | |
-10.26% | 4.74B | |
+18.88% | 4.52B | |
-0.88% | 3.91B | |
-0.16% | 3.74B | |
+3.91% | 3.43B |
- Stock Market
- Equities
- DXR Stock
- News Daxor Corporation
- Daxor Corporation Announces Pilot Randomized Controlled Trial Validates Daxor BVA-100 Diagnostic for Heart Failure Patients